Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery. Teleflex has annual revenues of $2.4 billion, operations in 40 countries, and more than 15,000 employees. By 2011, the company had substantially realigned to focus on its current business as a medical-device manufacturer, having undergone several years of active acquisitions and divestitures. Teleflex has been associated with Irish corporate tax avoidance tools. Teleflex's chief executive officer (CEO) is Liam J. Kelly; Kelly is also the company's president and former chief operating officer.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| TFX | TELEFLEX INC | 2026-04-02 16:17:32 | 115.53 | -2.28 | -1.94 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TFX | 0000096943 | TELEFLEX INC | US8793691069 | UUL85LWXB4NGSWWXIQ25 | 231147939 | NYSE | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 550 E SWEDESFORD RD | WAYNE | PA | 19087 | UNITED STATES | US | 610-225-6800 | 550 E SWEDESFORD RD, WAYNE, PA, 19087 | 550 E SWEDESFORD RD, WAYNE, PA, 19087 | — | — | 1943 | Liam J. Kelly | 15,000 | http://teleflex.com | 2,297,660,795 | 48,197,000 | 44,200,562 | Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery. Teleflex has annual revenues of $2.4 billion, operations in 40 countries, and more than 15,000 employees. By 2011, the company had substantially realigned to focus on its current business as a medical-device manufacturer, having undergone several years of active acquisitions and divestitures. Teleflex has been associated with Irish corporate tax avoidance tools. Teleflex's chief executive officer (CEO) is Liam J. Kelly; Kelly is also the company's president and former chief operating officer. | 2026-04-02 16:23:37 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 2,297,660,795 | -1,980,526,403 | -46.2936 | 44,200,562 | -2,165,901 | -4.6713 |
| 2024 | 4,278,187,198 | -1,355,903,129 | -24.0661 | 46,366,463 | -690,019 | -1.4664 |
| 2023 | 5,634,090,327 | -1,356,471,787 | -19.4043 | 47,056,482 | 112,327 | 0.2393 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| James P. Winters | Corporate Vice President | 2024 | 428,167 | 33,568 | 537,258 | 313,073 | 72,082 | 2,050,486 |
| Thomas E. Powell | Executive Vice President | 2024 | 659,475 | 49,461 | 959,709 | 516,646 | 181,930 | 3,560,335 |
| Liam J. Kelly | Chief Executive Officer, Chairman, President | 2024 | 1,106,950 | 138,369 | 2,744,215 | 1,445,344 | 358,212 | 9,204,397 |
| Jay K. White | Corporate Vice President, President | 2024 | 626,800 | 39,489 | 548,532 | 458,311 | 82,254 | 2,437,165 |
| Daniel V. Logue | Secretary, Corporate Vice President, General Counsel | 2024 | 435,675 | 30,497 | 532,556 | 318,562 | 57,202 | 2,036,411 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 15,500 |
| 2024 | 14,100 |
| 2023 | 14,500 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 1,992,713,000 | 3,047,324,000 | 2,974,489,000 |
| Cost Of Revenue | 871,959,000 | 1,344,645,000 | 1,327,558,000 |
| Gross Profit | 1,120,754,000 | 1,702,679,000 | 1,646,931,000 |
| Research And Development Expenses | 144,781,000 | 161,672,000 | 154,351,000 |
| General And Administrative Expenses | 720,169,000 | 995,271,000 | 929,867,000 |
| Operating Expenses | — | — | — |
| Operating Income | 118,373,000 | 151,013,000 | 506,313,000 |
| Net Income | -905,640,000 | 69,675,000 | 356,328,000 |
| Earnings Per Share Basic | -20.3 | 1.49 | 7.58 |
| Earnings Per Share Diluted | -20.25 | 1.48 | 7.53 |
| Weighted Average Shares Outstanding Basic | 44,622,000 | 46,837,000 | 46,981,000 |
| Weighted Average Shares Outstanding Diluted | 44,724,000 | 47,094,000 | 47,304,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 378,564,000 | 290,188,000 | 222,848,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 345,583,000 | 459,495,000 | 443,467,000 |
| Inventories | 404,395,000 | 600,133,000 | 626,216,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 1,938,338,000 | 1,471,124,000 | 1,407,406,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 498,281,000 | 502,852,000 | 479,913,000 |
| Other Assets Non Current | 112,984,000 | 102,624,000 | 98,943,000 |
| Total Assets Non Current | 5,008,901,000 | 5,626,790,000 | 6,125,140,000 |
| Total Assets | 6,947,239,000 | 7,097,914,000 | 7,532,546,000 |
| Accounts Payable | 130,201,000 | 141,031,000 | 132,247,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 100,000,000 | 100,000,000 | 87,500,000 |
| Other Liabilities Current | 137,195,000 | 67,243,000 | 46,547,000 |
| Total Liabilities Current | 762,026,000 | 649,360,000 | 606,745,000 |
| Long Term Debt | 2,641,449,000 | 1,655,871,000 | 1,815,072,000 |
| Other Liabilities Non Current | 194,532,000 | 102,307,000 | 162,502,000 |
| Total Liabilities Non Current | 3,060,445,000 | 2,170,414,000 | 2,484,813,000 |
| Total Liabilities | 3,822,471,000 | 2,819,774,000 | 3,091,558,000 |
| Common Stock | 48,197,000 | 48,096,000 | 48,046,000 |
| Retained Earnings | 3,149,760,000 | 4,115,870,000 | 4,109,736,000 |
| Accumulated Other Comprehensive Income | -239,468,000 | -316,669,000 | -314,405,000 |
| Total Shareholders Equity | 3,124,768,000 | 4,278,140,000 | 4,440,988,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 177,738,000 | 274,601,000 | 242,118,000 |
| Share Based Compensation Expense | 25,695,000 | 31,348,000 | 31,465,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 85,533,000 | 27,952,000 | 15,763,000 |
| Change In Inventories | -84,041,000 | -1,925,000 | 41,068,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -8,284,000 | 9,665,000 | -31,258,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 96,682,000 | 638,260,000 | 511,683,000 |
| Purchases Of Marketable Securities | 5,000,000 | 7,300,000 | 11,300,000 |
| Sales Of Marketable Securities | 0 | 7,300,000 | 7,300,000 |
| Acquisition Of Property Plant And Equipment | 95,236,000 | 126,434,000 | 91,442,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -36,538,000 | 0 | 0 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 60,470,000 | 63,541,000 | 63,896,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 303,044,000 | 201,895,000 | — |
| Issuance Of Long Term Debt | 1,140,000,000 | 130,000,000 | 646,000,000 |
| Repayment Of Long Term Debt | 153,000,000 | 291,500,000 | 544,750,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 611,539,000 | -421,925,000 | 38,540,000 |
| Change In Cash | 126,199,000 | 104,802,000 | -69,186,000 |
| Cash At End Of Period | 378,564,000 | 290,188,000 | 222,848,000 |
| Income Taxes Paid | 117,658,000 | 164,902,000 | 114,211,000 |
| Interest Paid | 119,337,000 | 98,376,000 | 100,218,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -20.3 | 1.49 | 7.58 |
| Price To Earnings Ratio | -6.0118 | 119.4497 | 32.8945 |
| Earnings Growth Rate | -1,462.4161 | -80.343 | -2.0672 |
| Price Earnings To Growth Ratio | 0.0041 | -1.4867 | -15.9127 |
| Book Value Per Share | 70.0275 | 91.341 | 94.5273 |
| Price To Book Ratio | 1.7427 | 1.9485 | 2.6378 |
| Ebitda | -510,021,000 | 592,722,000 | 797,739,000 |
| Enterprise Value | 7,808,553,880 | 9,801,732,260 | 13,393,966,540 |
| Dividend Yield | 0.0111 | 0.0076 | 0.0055 |
| Dividend Payout Ratio | -0.0668 | 0.912 | 0.1793 |
| Debt To Equity Ratio | 0.8773 | 0.4104 | 0.4284 |
| Capital Expenditures | 173,167,000 | 297,540,000 | 274,826,000 |
| Free Cash Flow | -76,485,000 | 340,720,000 | 236,857,000 |
| Return On Equity | -0.2898 | 0.0163 | 0.0802 |
| One Year Beta | 0.7513 | 0.6414 | 1.0487 |
| Three Year Beta | 0.7961 | 0.8761 | 0.9311 |
| Five Year Beta | 0.8512 | 0.9421 | 0.9618 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Winters James | Corp VP, Mfg and Supply | 2026-03-04 | 247 | D | 17,760 |
| Hicks Cameron P | Corp. VP & Chief HR Officer | 2026-03-04 | 98 | D | 19,362 |
| Deren John | Executive Vice President & CFO | 2026-03-04 | 229 | D | 18,073 |
| Logue Daniel V. | CVP, General Counsel & Secty | 2026-03-04 | 131 | D | 24,652 |
| Winters James | Corp VP, Mfg and Supply | 2026-03-03 | 3,262 | A | 8,262 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Susan M Collins | Senator | 2014-12-01 | Purchase | 2014-11-10 | Spouse | $15,001 - $50,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Lisa McClain | 2025-08-13 | MI09 | Sale | 2025-07-22 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-08-13 | MI09 | Purchase | 2025-07-16 | Spouse | $1,001 - $15,000 |
| Rob Bresnahan | 2025-03-27 | PA08 | Sale | 2025-02-25 | — | $1,001 - $15,000 |
| Daniel Goldman | 2023-08-13 | NY10 | Sale | 2023-07-12 | — | $15,001 - $50,000 |
| Daniel Goldman | 2023-05-19 | NY10 | Purchase | 2023-04-10 | — | $15,001 - $50,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| ROWLANDMILLER & PARTNERS.ADV | 2026-03-31 | 828,179 | 6,924 | 119.6099 |
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 14,322,869 | 117,362 | 122.0401 |
| HSBC HOLDINGS PLC | 2025-12-31 | 216,865 | 1,777 | 122.04 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 130,324 | 1,067 | 122.1406 |
| Eos Management, L.P. | 2025-12-31 | 3,762,615 | 30,831 | 122.04 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-01-31 | Invesco BuyBack Achievers ETF | PKW | 30,622 | 3,196,018.14 | 0.1984 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-01-31 | Invesco RAFI US 1000 ETF | PRF | 14,657 | 1,529,751.09 | 0.0172 |
| Catholic Responsible Investments Funds | 2026-01-31 | Institutional Shares | CRSSX | 17,999 | 1,878,555.63 | 0.3202 |
| Dunham Funds | 2026-01-31 | Dunham Small Cap Value Fund Class N | DNSVX | 8,397 | 876,394.89 | 0.94 |
| Dunham Funds | 2026-01-31 | Dunham Small Cap Value Fund Class C | DCSVX | 8,397 | 876,394.89 | 0.94 |